Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
December 2024's Promising US Penny Stocks

In This Article:

As December 2024 unfolds, the U.S. stock market presents a mixed landscape, with the Dow Jones Industrial Average marking its fifth consecutive day of gains while the S&P 500 and Nasdaq Composite see minor declines. In this context, investors often turn to penny stocks—smaller or newer companies that can offer significant opportunities despite their somewhat outdated name. By focusing on those with strong financial foundations and potential for growth, investors can uncover hidden value in these lesser-known equities.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.30

$1.85B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$103.25M

★★★★★★

BAB (OTCPK:BABB)

$0.84

$6.43M

★★★★★★

Pangaea Logistics Solutions (NasdaqCM:PANL)

$4.90

$234.98M

★★★★★☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.25

$8.83M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.85

$86.14M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.59

$49.54M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.62

$22.53M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9125

$76.47M

★★★★★☆

Click here to see the full list of 732 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Blade Air Mobility

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blade Air Mobility, Inc. offers air transportation alternatives to alleviate congested ground routes in the United States and has a market cap of approximately $325.79 million.

Operations: The company's revenue is derived from two main segments: Medical, which generated $142.42 million, and Passenger services, contributing $99.39 million.

Market Cap: $325.79M

Blade Air Mobility, Inc. has been actively pursuing strategic growth through acquisitions, with $140 million earmarked for tactical investments in its medical segment. Despite a market cap of approximately $325.79 million and revenue from medical ($142.42 million) and passenger services ($99.39 million), the company remains unprofitable, with a net loss of $17.51 million for the first nine months of 2024. The management team is experienced, and the company is debt-free with sufficient cash runway for over three years based on current free cash flow levels, though shareholder dilution has occurred recently by 4.9%.

NasdaqCM:BLDE Financial Position Analysis as at Dec 2024
NasdaqCM:BLDE Financial Position Analysis as at Dec 2024

Gevo

Simply Wall St Financial Health Rating: ★★★★★★


Waiting for permission
Allow microphone access to enable voice search

Try again.